Search research articles
Contact Us
Filters
Showing results (161-170 of 182) with videos related to
Page
of 19
Sort By:
Journal of Neurology
|
May 31, 2018
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study
Ian Marshall, Michael J Thrippleton, Mark E Bastin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 16, 2024
Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial
Maria A Rocca, Paola Valsasina, Francesco Romanò, et al.
Brain Communications
|
May 6, 2024
CSF neurofilament light chain profiling and quantitation in neurological diseases
Claire A Leckey, John B Coulton, Tatiana A Giovannucci, et al.
Neuroimage. Reports
|
September 27, 2024
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trial
Thomas Williams, Nevin John, Alberto Calvi, et al.
BMJ Open
|
September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
Peter Connick, Floriana De Angelis, Richard A Parker, et al.
The Lancet. Neurology
|
January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
Jeremy Chataway, Floriana De Angelis, Peter Connick, et al.
Nature Communications
|
April 8, 2025
Enabling new insights from old scans by repurposing clinical MRI archives for multiple sclerosis research
Philipp Goebl, Jed Wingrove, Omar Abdelmannan, et al.
Brain : a Journal of Neurology
|
October 8, 2021
The impact of smoking cessation on multiple sclerosis disease progression
Jeff Rodgers, Tim Friede, Frederick W Vonberg, et al.
BMJ Neurology Open
|
December 26, 2025
Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial
Kayla Ward, Vivien Li, Sudarshini Ramanathan, et al.
Journal of Neurology
|
June 26, 2026
The clinical, radiological and genetic spectrum AARS2-related leukoencephalopathy: a case series of 15 patients and review of the literature
Charles Wade, Anderson Rodrigues Brandão de Paiva, Paulo Ribeiro Nóbrega, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 182) with videos related to
Sort By:
Page
of 19
Journal of Neurology
|
May 31, 2018
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study
Ian Marshall, Michael J Thrippleton, Mark E Bastin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 16, 2024
Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial
Maria A Rocca, Paola Valsasina, Francesco Romanò, et al.
Brain Communications
|
May 6, 2024
CSF neurofilament light chain profiling and quantitation in neurological diseases
Claire A Leckey, John B Coulton, Tatiana A Giovannucci, et al.
Neuroimage. Reports
|
September 27, 2024
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trial
Thomas Williams, Nevin John, Alberto Calvi, et al.
BMJ Open
|
September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
Peter Connick, Floriana De Angelis, Richard A Parker, et al.
The Lancet. Neurology
|
January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
Jeremy Chataway, Floriana De Angelis, Peter Connick, et al.
Nature Communications
|
April 8, 2025
Enabling new insights from old scans by repurposing clinical MRI archives for multiple sclerosis research
Philipp Goebl, Jed Wingrove, Omar Abdelmannan, et al.
Brain : a Journal of Neurology
|
October 8, 2021
The impact of smoking cessation on multiple sclerosis disease progression
Jeff Rodgers, Tim Friede, Frederick W Vonberg, et al.
BMJ Neurology Open
|
December 26, 2025
Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial
Kayla Ward, Vivien Li, Sudarshini Ramanathan, et al.
Journal of Neurology
|
June 26, 2026
The clinical, radiological and genetic spectrum AARS2-related leukoencephalopathy: a case series of 15 patients and review of the literature
Charles Wade, Anderson Rodrigues Brandão de Paiva, Paulo Ribeiro Nóbrega, et al.
Page
of 19